Bruker Announces New Two-Year Share Repurchase Authorization of up to $500 Million; Board Declares Quarterly Dividend
15 Maio 2023 - 5:05PM
Business Wire
Bruker Corporation (Nasdaq: BRKR) today announced that on May
12, 2023, its Board of Directors approved a new share repurchase
authorization for the purchase of up to $500 million of the
Company’s common stock over a two-year period commencing on May 15,
2023.
The share repurchase authorization permits shares to be
repurchased under open market purchases, accelerated share
repurchases, or pursuant to trading plans intended to qualify under
Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The
share repurchase authorization does not obligate the Company to
repurchase any specific number of shares and may be suspended,
modified or terminated at any time without prior notice.
“Bruker’s strong financial performance, outlook, and balance
sheet continues to support a flexible capital allocation strategy
with our goal of maximizing shareholder value creation over the
long term,” said Gerald Herman, Executive Vice President and Chief
Financial Officer of Bruker. “This new share repurchase
authorization provides flexibility to selectively return capital to
our shareholders while continuing to prioritize investments which
enable innovation and sustainable growth over time, including in
our high-growth, high-margin, Project Accelerate 2.0
initiatives.”
Bruker Corporation also announced that its Board of Directors
approved payment of a quarterly cash dividend in the amount of
$0.05 per share on the Company's common stock. The dividend will be
paid on June 16, 2023 to stockholders of record as of June 1,
2023.
About Bruker Corporation (Nasdaq: BRKR) Bruker is
enabling scientists to make breakthrough discoveries and develop
new applications that improve the quality of human life. Bruker’s
high performance scientific instruments and high value analytical
and diagnostic solutions enable scientists to explore life and
materials at molecular, cellular, and microscopic levels. In close
cooperation with our customers, Bruker is enabling innovation,
improved productivity, and customer success in life-science
molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial research, semiconductor metrology and cleantech
applications. Bruker offers differentiated, high-value life science
and diagnostics systems and solutions in preclinical imaging,
clinical phenomics research, proteomics and multiomics, spatial and
single-cell biology, functional structural and condensate biology,
as well as in clinical microbiology and molecular diagnostics. For
more information, please visit: http://www.bruker.com/.
Forward-Looking Statements Any statements contained in
this press release which do not describe historical facts may
constitute forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including, but not
limited to, statements regarding our commitment to repurchasing our
shares at any level in the future, the anticipated value of shares
to be repurchased by us, the expected timing of such repurchases,
the availability of funds for the repurchase of shares,
management’s expectations for future financial and operational
performance and business outlook, strategic investments, our
Project Accelerate 2.0 initiatives and expected quarterly cash
dividends in 2023. Any forward-looking statements contained herein
are based on current expectations, but are subject to risks and
uncertainties that could cause actual results to differ materially
from those indicated, including, but not limited to, risk and
uncertainties relating to COVID-19, the length and severity of any
recession and the impact on global economic conditions, the impact
of supply chain challenges, including inflationary pressures, the
impact of geopolitical tensions and any sanctions, including any
reduction in natural gas exports from Russia resulting from its
ongoing conflict with Ukraine and resulting market disruptions,
such as higher prices for and reduced availability of key metals
used in our products, continued volatility in the capital markets,
the impact of increased interest rates, the integration and
assumption of liabilities of businesses we have acquired or may
acquire in the future, our restructuring and cost-control
initiatives, changing technologies, product development and market
acceptance of our products, the cost and pricing of our products,
manufacturing and outsourcing, competition, dependence on
collaborative partners, key suppliers and third party distributors,
capital spending and government funding policies, changes in
governmental regulations, intellectual property rights, litigation,
exposure to foreign currency fluctuations, the impact of foreign
currency exchange rates, our ability to service our debt
obligations and fund our anticipated cash needs, the effect of a
concentrated ownership of our common stock, loss of key personnel,
payment of future dividends and other risk factors discussed from
time to time in our filings with the Securities and Exchange
Commission, or SEC. These and other factors are identified and
described in more detail in our filings with the SEC, including,
without limitation, our annual report on Form 10-K for the year
ended December 31, 2022, as may be updated by our quarterly reports
on Form 10-Q. We expressly disclaim any intent or obligation to
update these forward-looking statements other than as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230515005748/en/
Justin Ward Sr. Director, Investor Relations & Corporate
Development Bruker Corporation T: +1 (978) 313-5800 E:
Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Bruker (NASDAQ:BRKR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024